The weekly litigation news digest is live. Subscribe now
Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile - EP3070090
The patent EP3070090 was granted to Incyte on Dec 12, 2018. The application was originally filed on Jun 12, 2008 under application number EP16152794A. The patent is currently recorded with a legal status of "Revoked".
EP3070090
- Application Number
- EP16152794A
- Filing Date
- Jun 12, 2008
- Status
- Revoked
- Nov 26, 2021
- Publication Date
- Dec 12, 2018
- External Links
- Slate, Register, Google Patents
Patent Summary
Salt forms of a JAK inhibitor drug called (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile for treating polycythemia vera. The salt forms include maleic, sulfuric, and phosphoric acid salts. These salt forms provide improved solubility and bioavailability compared to the free base form. Administering the salt forms in combination with corticosteroids like dexamethasone can improve efficacy for treating diseases associated with JAK expression or activity.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (28) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents